How much funding has Eugit Therapeutics raised?

Eugit Therapeutics has raised $775K in total funding, most recently a Grant round.

Who are Eugit Therapeutics's investors?

Eugit Therapeutics's investors include US National Science Foundation, Y Combinator Continuity Fund.

When was Eugit Therapeutics founded?

Eugit Therapeutics was founded in 2022.

Where is Eugit Therapeutics headquartered?

Eugit Therapeutics is headquartered in San Carlos, California, United States.

What industry is Eugit Therapeutics in?

Eugit Therapeutics operates in Biotech, Healthcare, Oncology, Synthetic Biology, Therapeutics.

How many employees does Eugit Therapeutics have?

Eugit Therapeutics has 1-10 employees.

Eugit Therapeutics

Enabling Tissue Targeting of Therapies

San Carlos, United States · Founded 2022 · $775K raised

YC S22

Headquarters: San Carlos, California
Employees: 1–10
Founded: 2022
Website: eugittx.com

Total Funding: $775K
Last Round: $275K GrantAug 2024
Rounds: 2

About

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Summary

Eugit Therapeutics is a Biotech company based in San Carlos, United States, founded in 2022. It has raised $775K in total across 2 rounds, most recently a $275K Grant round in Aug 2024. Investors include US National Science Foundation and Y Combinator Continuity Fund.